aussie of year applauds relenza, page-4

bta management option rewards! it is disconcerting to see a less than proactive bta management in these circumstances yet being rewarded with millions of options by virtue of the waywardness of migratory birds. without gsk co-operating to benefit shareholders( if indeed they intended it so to be for a cheap takeover) the least we can expect of bta management is to emulate cos like vcr ptd smy keeping positive news in the frontline.

some of them even put brokers' research reports on their websites to promote a better understanding of the stock in investing circles. whenever necessary even non-broker independent research co reports are posted. often they appear as interviews with key management people and are reported to asx as a general update of products/business conditions.

my impression is that they are naivettes in the corporate world - compare them with biocryst management and their way of feeding the market gallery on nasdaq with publicity of a phase 1 trial product!